Navigation Links
BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Date:9/21/2009

BIRMINGHAM, Ala., Sept. 21 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.

"We are very excited to continue working with the U.S. government to advance the development of peramivir," said Jon P. Stonehouse, President and Chief Executive Officer, BioCryst Pharmaceuticals. "Peramivir is being developed with HHS to treat seriously ill and hospitalized patients, with the goal of saving lives. This contract modification supports peramivir's Phase 3 clinical development with the aim of gaining U.S. regulatory approval."

"There are currently no anti-viral drugs approved to treat seriously ill patients with influenza who need hospital care," said Dr. William P. Sheridan, Chief Medical Officer at BioCryst. "BioCryst is committed to working with the U.S. government to advance the development of peramivir to address unmet medical needs for an intravenous treatment for influenza. We intend to initiate our Phase 3 studies as soon as possible."

This contract modification brings the total award from HHS for the development of peramivir to $179.9 million and extends the contract term by 12 months to five years. BioCryst was originally awarded a $102.6 million, four-year contract from the HHS to develop peramivir for the treatment of influenza in January 2007. Under the original contract, peramivir was advanced through Phase 2 and the initial steps of Phase 3 development.

Phase 3 Development of peramivir

BioC
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst to Present at UBS Global Life Sciences Conference
2. BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
3. BioCryst Executives to Present at Two Investor Conferences
4. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
5. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
6. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
7. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
8. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
9. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... EurekaMag.com has newly published results of ... contagious liver disease that ranges in severity from ... serious, lifelong illness that attacks the liver. An estimated ... Hepatitis C virus infection of which approximately 80% of ... category covers all studies on Hepatitis C , the ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
(Date:7/14/2014)... WI (PRWEB) July 14, 2014 Doctor ... announced the launch of their new company website. The ... valuable free information on chiropractic marketing. It's also a ... that Inception has to offer. , When contacted at ... the newest version of our main website. Our site ...
(Date:7/14/2014)... Essex, CT (PRWEB) July 14, 2014 Summer ... means vacations, camping, days at the beach, swimming and other ... want everyone to be safe, happy and healthy all summer ... of a list of the three must-have custom imprinted products ... first summer essential is of course sunblock. Sunscreen ...
(Date:7/13/2014)... 2014 Save the Date for the 2014 ... Jacksonville, FL , BOXWOODS & BowTies “A Modern Twist on ... The Women’s Board of Wolfson Children’s Hospital will ... to continue their ongoing commitment to raising funds for the ... , What: The 2014 Art & Antiques Show is a ...
Breaking Medicine News(10 mins):Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 2Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 3Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 4Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 5Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 6Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 7Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 8Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 9
... 21 LUMEDX Corporation, a leading,provider of ... introduces software to manage data and track ... Module empowers clinicians,by making critical clinical information ... For more information -- including a free ...
... May 20 The U.S. Department of,Health and ... advertising,campaign focusing on the quality of care available ... HHS, Centers for Medicare & Medicaid Services (CMS),in ... newspapers, promote Hospital,Compare ( http://www.hospitalcompare.hhs.gov ), an easy-to-use ...
... researchers,found that the frequency with which critically-ill patients ... a,multidisciplinary medical center such as Mayo Clinic compared ... the National Healthcare Safety,Network (NHSN). This is good ... are generally strong across the U.S. in intensive ...
... 2008) A newly published study presents data ... (COPD), including emphysema and chronic bronchitis, experienced markedly ... a combination of nebulized formoterol fumarate inhalation solution ... treatment with tiotropium alone. The two medications, ...
... BEDFORD, Mass., May 20 Hologic, Inc. (Nasdaq:,HOLX) today ... at the NASDAQ 21st Investor Program being held May ... parties are invited to listen to a live audio ... at 10:45 a.m.,BST on the investor section of the ...
... One of 35,000 Doctors Now Using E-Prescribing, ... (PCMA) is unveiling a new print ad campaign ... successfully use electronic,prescribing (e-prescribing) technology and who also ... new ad features Dr. R. David Allard, a ...
Cached Medicine News:Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 3Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 2Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 3Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 4Health News:PCMA's New Ad Campaign: E-Prescribing is Ready Now 2
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... N.Y. , July 6 E. Fougera & ... first generic approval from the FDA for Adapalene Cream 0.1% ... to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. ... $55 million . This approval also marks the fourth product ...
... PARSIPPANY, N.J. , July 6 July 5th is ... in the state of Wisconsin and every year almost 7,200 of them ... an added incentive to quit with the Wisconsin smoke free law that ... , , ...
Cached Medicine Technology:Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 2Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 3Wisconsin Statewide Smoke-Free Law May Prompt Smokers to Quit 2Wisconsin Statewide Smoke-Free Law May Prompt Smokers to Quit 3
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
10L...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: